Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Dementia × Lymphoid × Clear all

Phase

Phase NA 39 Phase 3 3 Phase 2/3 1 Phase 2 1 Phase 1 1

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 41 Lymphoma 21 Leukemia 17 Lymphoma, Large B-Cell, Diffuse 16 Lymphoma, Non-Hodgkin 14 Lymphoma, Follicular 12 Leukemia, Myeloid, Acute 10 Neoplasms 9 Myelodysplastic Syndromes 9 Recurrence 6 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6 Leukemia, Lymphocytic, Chronic, B-Cell 6 Hematologic Neoplasms 6 Multiple Myeloma 5 Lymphoma, Mantle-Cell 5 Hodgkin Disease 5 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4 Neoplasms, Plasma Cell 4 Lymphoma, B-Cell, Marginal Zone 4 Leukemia, Biphenotypic, Acute 4 Infections 4 Graft vs Host Disease 4 Burkitt Lymphoma 4 Anemia, Refractory, with Excess of Blasts 4 Lymphoma, T-Cell, Peripheral 3 Leukemia, T-Cell 3 Leukemia, Myeloid, Chronic-Phase 3 Leukemia, Myeloid, Accelerated Phase 3 Waldenstrom Macroglobulinemia 2 Sezary Syndrome 2

Interventions

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06125951 2026-02-18

XanaMIA

Actinogen Medical

Phase 2/3 Active not recruiting

Alzheimer Disease, Dementia, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon ⚡